Understanding LGALS9: A Potential Drug Target for Placenta and Beyond

Target Name: LGALS9

NCBI ID: G3965

LGALS9

Understanding LGALS9: A Potential Drug Target for Placenta and Beyond

LGALS9 (Ecalectin) is a protein that is expressed in the human placenta and has been shown to play a role in several important physiological processes in the body. It is a potential drug target or biomarker that could be used to treat various diseases, including cancer, infertility, and cardiovascular disease.

LGALS9 is a transmembrane protein that is expressed in the human placenta, meaning that it is produced and exists primarily within the cell membrane. It is composed of four distinct chains that are held together by disulfide bonds. The two long chains contain the extracellular portion of the protein, while the two short chains are located within the intracellular portion.

One of the unique features of LGALS9 is its ability to interact with other proteins that are expressed in the placenta, including the protein PDGF-BB. This interaction between LGALS9 and PDGF-BB has been shown to play a role in several important physiological processes, including fetal development and placential function.

In addition to its interaction with PDGF-BB, LGALS9 has also been shown to interact with several other proteins that are involved in the development and maintenance of the placenta. These include the transcription factors PDX1 and NF-kappa-B, as well as the signaling proteins Fas and Notch.

The role of LGALS9 in fetal development is still being fully understood. However, studies have shown that LGALS9 plays a critical role in the development and maintenance of the neural tube, which forms the baby's brain and spinal cord. LGALS9 has been shown to promote the formation of the neural tube by driving the expression of genes that are involved in this process.

In addition to its role in fetal development, LGALS9 has also been shown to play a critical role in the function of the placenta. Studies have shown that LGALS9 helps to regulate the growth and differentiation of the placenta, and that it is involved in the production of several important proteins that are involved in placental function.

As a potential drug target or biomarker, LGALS9 has the potential to be used to treat a wide range of diseases. For example, it has been shown to be involved in several forms of cancer, including breast, ovarian, and prostate cancer. Additionally, LGALS9 has also been shown to be involved in infertility, with studies showing that it is involved in the development and function of the eggs.

In addition to its potential use in treating cancer and infertility, LGALS9 has also been shown to have potential applications in the treatment of other diseases. For example, studies have shown that LGALS9 can be used to treat sepsis, a life-threatening condition that occurs when the body's response to an infection becomes uncontrolled and can cause widespread inflammation.

In conclusion, LGALS9 (Ecalectin) is a protein that is expressed in the human placenta and has been shown to play a critical role in several important physiological processes in the body. Its ability to interact with other proteins that are involved in the development and maintenance of the placenta makes it a potential drug target or biomarker that could be used to treat a wide range of diseases. Further research is needed to fully understand the role of LGALS9 in fetal development and placental function, as well as its potential applications in the treatment of cancer, infertility, and other diseases.

Protein Name: Galectin 9

Functions: Binds galactosides (PubMed:18005988). Has high affinity for the Forssman pentasaccharide (PubMed:18005988). Ligand for HAVCR2/TIM3 (PubMed:16286920). Binding to HAVCR2 induces T-helper type 1 lymphocyte (Th1) death (PubMed:16286920). Also stimulates bactericidal activity in infected macrophages by causing macrophage activation and IL1B secretion which restricts intracellular bacterial growth (By similarity). Ligand for P4HB; the interaction retains P4HB at the cell surface of Th2 T-helper cells, increasing disulfide reductase activity at the plasma membrane, altering the plasma membrane redox state and enhancing cell migration (PubMed:21670307). Ligand for CD44; the interaction enhances binding of SMAD3 to the FOXP3 promoter, leading to up-regulation of FOXP3 expression and increased induced regulatory T (iTreg) cell stability and suppressive function (By similarity). Promotes ability of mesenchymal stromal cells to suppress T-cell proliferation (PubMed:23817958). Expands regulatory T-cells and induces cytotoxic T-cell apoptosis following virus infection (PubMed:20209097). Activates ERK1/2 phosphorylation inducing cytokine (IL-6, IL-8, IL-12) and chemokine (CCL2) production in mast and dendritic cells (PubMed:24465902, PubMed:16116184). Inhibits degranulation and induces apoptosis of mast cells (PubMed:24465902). Induces maturation and migration of dendritic cells (PubMed:25754930, PubMed:16116184). Inhibits natural killer (NK) cell function (PubMed:23408620). Can transform NK cell phenotype from peripheral to decidual during pregnancy (PubMed:25578313). Astrocyte derived galectin-9 enhances microglial TNF production (By similarity). May play a role in thymocyte-epithelial interactions relevant to the biology of the thymus. May provide the molecular basis for urate flux across cell membranes, allowing urate that is formed during purine metabolism to efflux from cells and serving as an electrogenic transporter that plays an important role in renal and gastrointestinal urate excretion (By similarity). Highly selective to the anion urate (By similarity)

The "LGALS9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LGALS9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets